Gender difference in antidiuretic response to desmopressin

Area of Science:

• Pharmacology
• Endocrinology
• Urology

Background:

• Female gender and advanced age are established risk factors for desmopressin-induced hyponatremia.
• Limited research has explored potential gender disparities in the antidiuretic response to desmopressin.

Purpose of the Study:

• To investigate gender differences in the efficacy and safety of desmopressin for treating nocturia.
• To explore potential gender-based variations in desmopressin's antidiuretic effects and hyponatremia risk.

Main Methods:

• Exploratory analysis of data from three clinical trials involving desmopressin treatment for nocturia.
• Assessment of desmopressin's effects on nocturnal urine volume and serum sodium levels, with analysis of pharmacokinetic parameters.
• Statistical modeling to determine dose-response relationships and estimate median effective dose (ED50) stratified by gender.

Main Results:

• Women exhibited a significantly greater decrease in nocturnal urine volume compared to men, particularly at lower desmopressin doses (10 and 25 μg).
• The estimated ED50 for desmopressin was substantially lower in women (16.1 μg) than in men (43.2 μg), indicating higher sensitivity.
• Hyponatremia incidence increased with dose, with women over 50 experiencing approximately twofold greater serum sodium decreases than men at the 100 μg dose.

Conclusions:

• Significant gender differences exist in desmopressin's efficacy and safety profile for nocturia treatment.
• Women demonstrate heightened sensitivity to desmopressin's antidiuretic effects and a greater risk of hyponatremia.
• Gender-stratified dosing recommendations for desmopressin are proposed: 50-100 μg for men and 25 μg for women, to optimize efficacy and minimize hyponatremia risk.